TIGIT在泌尿系統(tǒng)腫瘤中的研究進(jìn)展

打開文本圖片集

Research progress of TIGIT in urinary system tumors

ABSTRACT：T cell immunoglobulin and immune receptor tyrosine-based inhibitory motif domain （TIGIT） is a co-inhibitory receptor，which is highly expressed in a variety of malignant tumors.It can inhibit T cells and NK cells，and plays a key role in regulating immune response and tumor immune escape.TIGIT is closely related to the growth，metastasis and prognosis of urologic tumors，and its overexpression is associated with tumor progression and poor prognosis.Currently，TIGIT-based urologic tumors treatment strategies include monoclonal antibody therapy and combined immunotherapy，such as combination therapy with PD-1/PD-L1 and other drugs.Experimental and clinical studies on TIGIT are also being carried out and significant progress has been made.Therefore，TIGIT is expected to become a new target for immunotherapy and a biomarker for predicting the prognosis of patients with urologic tumors.This article reviews the research progress of TIGIT in urologic tumors.

KEY WORDS：T cell immunoglobulin and immune receptor tyrosine-based inhibitory motif domain; kidney cancer; bladder cancer; prostate cancer; urogenital system tumor；programmed cell death protein-1

摘要：T細(xì)胞免疫球蛋白和酪氨酸抑制基序結(jié)構(gòu)域蛋白（TIGIT）是一種共抑制性受體，在多種惡性腫瘤中高表達(dá)，能夠?qū)細(xì)胞及自然殺傷（NK）細(xì)胞起到功能抑制作用，在調(diào)節(jié)免疫反應(yīng)和腫瘤免疫逃逸中扮演著關(guān)鍵角色。（剩余12433字）